Strados Labs logo

Chronic Obstructive Pulmonary Disease (COPD)

Manage COPD from Hospital to Home with Real-Time Monitoring of Cough and Wheeze

Chronic Obstructive Pulmonary Disease (COPD) places a significant burden on healthcare systems, with readmission rates often exceeding 20% within 30 days.1

Traditional methods of assessing respiratory status in COPD patients remotely have limitations, with patient self-reporting less consistent than objective methods and auscultation with a stethoscope limited to episodic, in-person visits. FEV1, while valuable in measuring disease progression is not used to prevent exacerbations and lacks insight into patient quality of life.2

New innovations have been developed to offer clinicians and patients greater control over exacerbations and insight into respiratory status remotely, with objective monitoring of cough and lung sounds emerging as a promising approach.3 Increased cough and wheezing are common early warning signs of deterioration for patients, with studies showing that increased coughing can predict exacerbations up to 3.4 days in advance.4

Collect Reliable, Accurate Lung Sound Data from COPD Patients Anywhere, Anytime

The RESP® Biosensor offers clinicians and researchers an objective way to measure symptoms like cough, wheeze and crackles associated with COPD.
  • Clinically validated accuracy, with equivalent performance to Littman 3200 stethoscope.
  • Continuous monitoring of cough and lung sounds to offer quantitative data on respiratory symptoms over time.
  • Patient-friendly, reduces the burden on patients while improving clinician efficiency.

Certifications: FDA 510(k) clearance, CE Mark, HIPAA Compliant

Strados Cough Monitoring Solution

Case Study of a COPD Patient

  • The RESP Biosensor was used to independently track lung sounds of a 49-year-old male admitted for acute exacerbations of COPD.
  • After 4 days, the patient was discharged based on traditional functional lung indicators. However, the RESP Biosensor showed a 44% increase in cough and a 119% increase in wheeze between day 3 and 4 prior to discharge.
  • The patient was ultimately readmitted 5 days after discharge; the RESP Biosensor could be used to predict clinical worsening, guide early intervention, and avoid readmission.

Download the Strados Publication

Increasing Abnormal Lung Sounds After Discharge for COPD Exacerbation Predicts Readmission

Healthcare Settings

Manage lung health from hospital to home with real-time monitoring of symptoms

Learn More

Life Sciences

Gain greater, objective insight into subject treatment response in clinical trials

Learn More

Expert Overread Process

  • Our team of trained respiratory therapists and labelers review subject lung sound recordings to meet regulatory and clinical requirements for data accuracy.
  • Machine learning algorithms* have been trained based on validated cough and lung sound events and performance tested to meet customer requirements.
  • Algorithms* can be used independently or to assist in the overread process.

*Machine learning algorithms not FDA-cleared

Lung sound recordings are depicted as spectrograms to facilitate overread
Cough graph

Cough

Wheeze graph

Wheeze

Crackles graph

Crackles

Clinical Validation

Explore our peer reviewed performance testing, studies and publications.
Increasing Abnormal Lung Sounds in COPD Predicts Readmission
Objective Cough Monitoring Detects More Patients with Cough Than Patient Self-Reporting
Results of Clinical Performance Testing in Chronic Lung Diseases

How is data collected by the RESP® Biosensor transferred to the cloud?

Lung sound recordings captured by the RESP® Biosensor are transferred via Bluetooth to a companion patient mobile app, and from there is sent to the Strados cloud via Wi-Fi or cellular data.

How exactly are the lung sound events (i.e. cough, wheeze) detected and annotated?

We have developed a validated overread process that includes our team of respiratory therapists and specialists who manually review lung sound recordings to meet regulatory and clinical requirements for data accuracy.

Our machine learning algorithms have also been trained based on clinically validated labeled data and performance tested to meet customer requirements. Algorithms can be used independently for event detection or to feed data to our validated overread process.

How long do COPD patients typically wear the RESP® Biosensor?

The RESP® Biosensor is often worn for 24-hour periods in clinical trials and has roughly a 25-hour battery life. However, patients can wear the device anywhere from 7 days to 30 days. Patients are given two devices and if they’re instructed to wear the device on consecutive days; they will need to replace the device with a fully charged one after the battery runs out every 24 hours.

Let’s Talk

Explore using the RESP Biosensor with your COPD patients

Contact Us

References

  1. Li, M., Cheng, K., Ku, K., Li, J., Hu, H., & Ung, C. O. L. (2023). Modelling 30-day hospital readmission after discharge for COPD patients based on electronic health records. NPJ primary care respiratory medicine, 33(1), 16. https://doi.org/10.1038/s41533-023-00339-6
  2. van der Molen, T., Miravitlles, M., & Kocks, J. W. (2013). COPD management: role of symptom assessment in routine clinical practice. International journal of chronic obstructive pulmonary disease, 8, 461–471. https://doi.org/10.2147/COPD.S49392
  3. Wang, J. M., Han, M. K., & Labaki, W. W. (2022). Chronic obstructive pulmonary disease risk assessment tools: is one better than the others?. Current opinion in pulmonary medicine, 28(2), 99–108. https://doi.org/10.1097/MCP.0000000000000833
  4. Crooks, M. G., den Brinker, A. C., Thackray-Nocera, S., van Dinther, R., Wright, C. E., & Morice, A. H. (2021). Domiciliary Cough Monitoring for the Prediction of COPD Exacerbations. Lung, 199(2), 131–137. https://doi.org/10.1007/s00408-021-00435-9